TolDCB29
Alternative Names: Autologous mature tolerogenic monocyte-derived dendritic Cells loaded with the B29 peptide of HSP70; TolDCB29 therapyLatest Information Update: 16 Mar 2022
At a glance
- Originator Trajectum Pharma
- Class Dendritic cell vaccines; Synthetic vaccines
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Rheumatoid arthritis
Most Recent Events
- 07 Mar 2022 Trajectum Pharma has patent protection for technology related to B29 peptide of HSP70 before March 2022 (Trajectum Pharma website, March 2022)
- 07 Mar 2022 Trajectum Pharma intends to obtain approval and further launch for TolDCB29 (Trajectum Pharma website, March 2022)
- 07 Mar 2022 Trajectum Pharma plans a phase III pivotal trial in Rheumatoid arthritis (Trajectum Pharma website, March 2022)